“Sirtex develops oncology treatments using novel small particle technology to improve outcomes for patients with cancer. SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation via the hepatic artery during Selective Internal Radiation Therapy (SIRT). Data shared at the 2015 ASCO Annual Meeting showed a 7.9 month improvement in Progression-Free Survival in the liver for patients with unresectable mCRC treated first line with SIR-Spheres microspheres plus standard chemotherapy.
.